# Won Ki Kang

Source: https://onco.cc/people/kang-won-ki/  
OnCo record `kang-won-ki` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A senior gastric cancer oncologist whose adjuvant and perioperative trials in Korea helped define post-gastrectomy chemotherapy.

## Summary

Won Ki Kang is Professor of Medical Oncology at Samsung Medical Center in Seoul, specialising in gastrointestinal oncology. A senior gastric cancer oncologist, he has led Korean multicentre trials including the ARTIST studies of adjuvant chemoradiation, which helped define chemotherapy after gastrectomy, and has been an investigator on first-line immunotherapy trials such as CheckMate 649 and on HER2 trials. His publications include the ARTIST phase 3 trial of adjuvant capecitabine and cisplatin with or without radiotherapy in D2-resected gastric cancer. His interests are gastric cancer, adjuvant chemotherapy and clinical trials.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Professor of Medical Oncology; gastrointestinal oncology
- Specialisms: Gastric cancer; Adjuvant chemotherapy; Clinical trials

## Sources

- Samsung Medical Center: https://www.samsunghospital.com/gb/
- PubMed author search: https://pubmed.ncbi.nlm.nih.gov/?term=Kang%20WK%5BAuthor%5D%20gastric%20cancer%20Samsung

## Connected records

- cancers: [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/)
- institutions: [Samsung Medical Center](https://onco.cc/institutions/samsung-medical-center/)
- trials: [CheckMate 649](https://onco.cc/trials/checkmate-649/)

---
JSON: https://onco.cc/api/v1/entities/kang-won-ki.json